FindTrial
Sign In

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00650390
Acronym
PROWD
Enrollment
Unknown
Registered
2008-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2008-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance. To explore the safety of adalimumab in subjects previously treated with infliximab.

Interventions

BIOLOGICALadalimumab

40 mg adalimumab every other week

Sponsors

Abbott
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Males and females \>= 18 years of age * ACR criteria for RA diagnosis for at least 6 months * Active RA defined as a DAS 28 \>3.2 at study entry * Unsatisfactory response, loss of response or intolerance to prior infliximab treatment * A negative pregnancy test for females of childbearing potential

Exclusion criteria

* Patient who had previous treatment with cyclophosphamide and chlorambucil * Treatment within the last 8 weeks with infliximab * Prior treatment with more than one DMARD or DMARD combination following infliximab treatment * Prior treatment with biologics (Investigational or Commercial) RA therapies other than infliximab * History of cancer, other than successfully treated squamous cell or basal cell carcinoma or lymphoproliferative disease * Prior treatment with total lymphoid irradiation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026